gip glp 1 medications The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Understand GLP-1/GIP Dual Agonist Tirzepatide

A sudden or excessive drop in blood sugar levels can disrupt blood flow, increasing the risk of ischemic events in the eye

Spiazzi BF, Naibo RA, Wayerbacher LF, Piccoli GF, Farenzena LP, Londero TM, da Natividade GR, Zoldan M, Degobi NAH, Niches M, Lopes G, Boyko EJ, Utzschneider KM, Colpani V, Gerchman F

Implications for the pharma supply chain: With cash-pay GLP-1 prices dropping sharply, employers have a new, more cost-effective way to cover these drugs: sidestep the traditional pharma supply chain, secure better pricing than PBM terms, and gain greater transparency into pharmacy spending

For non-IBD IMIDs, there were three human in vitro studies and eight human clinical studies